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Abstract
As HIV becomes a chronic infection, an increasing number of HIV-infected patients are travelling to malaria-
endemic areas. Association of malaria with HIV/AIDS can be clinically severe. Severe falciparum malaria is a medical
emergency that is associated with a high mortality, even when treated in an Intensive Care Unit. This article
describes two cases of HIV-positive patients, who returned from malaria-endemic areas and presented a
parasitaemia > 5% of erythrocytes and clinical signs of severe falciparum malaria, both with > 350 CD4 cell count/
μl, absence of chemoprophylaxis and successful response. Factors like drug interactions and the possible
implication of anti-malarial therapy bioavailability are all especially interesting in HIV-malaria co-infections.
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Background
Plasmodium falciparum imported malaria causes severe
clinical episodes every year in European travellers.
Between 2% and 16% of these infections are severe cases
according to the World Health Organization (WHO)
definition [1-3]. Currently, the travellers’ profile presents
great diversity. An increasing number of patients with
human immunodeficiency virus (HIV) are travelling to
malaria-endemic areas [4]. Studies about countries
where malaria is endemic suggest that the patients with
a low CD4 T cell count or advanced HIV-1 disease had
an increased risk of malaria events, higher parasitaemia
and more severe clinical episodes [5-9]. Other authors
have reported that the impact of HIV infection on the
severity of an imported malaria infection is restricted to
patients with CD4 cell counts < 350 cells/μL [10]. There-
fore, factors such as the interaction between anti-malarial
drug and anti-retroviral therapy are important in the
management of clinical malaria episodes. Artemisinin-
based combination therapies and a parenteral therapy
combination with artesunate are now accepted as the
first-line recommendations by WHO for the treatment of
uncomplicated and severe malaria, respectively. However,
there are no anti-malarial treatment guidelines for HIV-
infected patients. Parasitological response to treatment of
acute malaria among HIV-sero-positive individuals has
not been evaluated [11].
Two clinical cases of imported P. falciparum malaria
in two HIV-infected patients are presented and dis-
cussed, because of the possibility of improved diagnosis
methods needed on admission or for follow-up anti-
malarial therapy.
Case presentation
Case report 1
A 47-year-old man from Spain presented in University
Hospital La Paz in Madrid, Spain, with a two-day history
of intermittent fever, headache and fatigue. The patient
had returned a week earlier from a four-week trip to
Equatorial Guinea. He did not take anti-malarial chemo-
prophylaxis during the visit. He was a category A3 HIV-
infected patient with a CD4 cell count of 650/μL and
HIV viral load of less than 20 copies/mL. He had been
taking tenofovir, emtricitabine and efavirenz since 2008.
On examination, he was febrile (38.7°C) and had a heart
rate of 120 beats/min, blood pressure of 93/64 mmHg,
normal respiration rate and oxygen saturation 95% on
room air. Laboratory investigations showed normal hae-
moglobin concentration (14.8 gr/dL), normal cell count
and leukocyte formula (4.4 × 109 cells/L, N 89.1%, L 6.9%
M 1.6%), moderate thrombocytopaenia (36 × 109 cells/L,
reference range 125-350 × 109 cells/L), normal glucose
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levels (110 mg/dL), bilirubin (28 μmol/L, reference value
< 20 μmol/L), creatinine (176 μmol/L, reference range
40-120 μmol/L) and slightly increased aspartate transa-
minase (82 UI/L, normal < 37 UI/L) and an elevated
C-reactive protein concentration of 157 mg/L (normal <
10 mg/L). Malaria parasites were seen on Giemsa-stained
thick and thin blood films with Field’s stain in 7% of ery-
throcytes. Parasite morphology identified P. falciparum.
A rapid diagnostic test (RDT) result for histidine-rich
protein 2 of P. falciparum (Now® Malaria Test, Binax
INC, Maine, USA) was positive. Results of multiplex PCR
assay, species-specific nested-PCR [12] were positive for
P. falciparum. The patient was admitted to the intensive
care unit with several signs of severe malaria (parasitae-
mia of 7% of erythrocytes, haemodynamic instability,
decreased level of consciousness, respiratory distress syn-
drome and mild renal insufficiency) for monitoring.
Patient was treated with quinine and doxycycline intrave-
nous for seven days at the recommended doses in adults.
The anti-retroviral therapy with tenofovir, emtricitabine
and efavirenz was not interrupted. On day 2 the parasi-
taemia was 1%. The parasites were cleared after six days
without recrudescence. The hospital stay lasted 13 days.
Case report 2
A 38-year-old man from France presented to University
Hospital La Paz, with a two-day history of fever, sweating,
abdominal pain and vomiting after returning from a six-
day visit to the Ivory Coast. He did not use personal vec-
tor avoidance measures (insect repellent, long-sleeved
clothing, netting). He had not taken anti-malarial chemo-
prophylaxis. He had been diagnosed with HIV infection
10 years before. He was taking tenofovir, abacavir and
darunavir/ritonavir with a CD4 cell count of 432/μL and
undetectable viral load (less than 20 copies/mL). He was
admitted to the emergency department with a tempera-
ture of 39.9°C but he was in good general condition with
a normal respiratory rate, blood pressure of 147/88
mmHg, and normal oxygen saturation. The day of admis-
sion, laboratory investigations revealed: normal haemo-
globin concentration (15,0 gr/dL), normal white cell
count and leukocyte formula (6.3 × 109 cells/L, N 78.3%,
L 12.3%, M 8.5%), moderate thrombocytopaenia (91 ×
109 cells/L, reference range 125-350 × 109 cells/L), nor-
mal glucose levels (104 mg/dL), bilirubin (1.6 μmol/L,
reference value < 20 μmol/L), creatinine (135 μmol/L,
reference range 40-120 μmol/L) and slightly increased
aspartate transaminase (95 UI/L, normal < 37 UI/L) and
ALT (92 UI/L, normal < 65 UI/L) and an elevated C-
reactive protein concentration of 112 mg/L (normal < 10
mg/L). Malaria parasites were detected by microscopic
examination in 0.5% of his erythrocytes. The RDT (Now®
Malaria Test, Binax INC, Maine, USA) was positive for
P. falciparum. The patient was treated with atovaquone/
proguanil 250 mg/100 mg, every six hours for three days.
On day 3, he was again febrile with P. falciparum parasi-
taemia nearly 8% of erytrocytes. His laboratory results
showed a decreased haemoglobin concentration of 10.0
gr/dL and thrombocytopaenia more severe than 33 × 109
cells/L. Anti-malarial treatment was changed to intrave-
nous quinine and doxycycline for seven days and was
monitored in the intensive care unit for the first 24
hours. The anti-retroviral therapy with tenofovir, abaca-
vir and darunavir/ritonavir was stopped, after initiating
the malarial treatment with quinine. On day 6 he was
cleared of parasitaemia. He was discharged after 10 days.
The multiplex PCR assays performed on the sample col-
lected on the day of admission confirmed that the patient
was only infected with P. falciparum. Analysis of point
mutations in the cytochrome b gene, related to resistance
to atovaquone, and in the dihydrofolate reductase
(DHFR) gene, related to proguanil resistance, show a sin-
gle mutation in the cytochrome b gene (L283I) and four
point mutations for the DHFR gene (Table 1).
Conclusions
Plasmodium falciparum parasitaemia is higher in HIV-
infected patients, especially in those with a low CD4 cell
count [5-10]. In the first case, the patient had a parasitae-
mia of 7% in the blood smear at the time of diagnosis
and a 650 CD4 T cell count/μl. A parasitaemia above 5%
in non-immune travellers for malaria falls within the
severity criteria according to WHO definition. Older age,
European origin, travel to eastern Africa, absence of che-
moprophylaxis, time to diagnosis of four to 12 days and
diagnosis during the fall-winter season have been asso-
ciated with severe imported P. falciparum malaria in
non-immune travellers [2]. Data about the impact of
HIV-1 infection on the severity of imported P. falci-
parum malaria have been reported and the most frequent
criterion of severity was hyperparasitaemia [10]. There
are few clinical trials on the co-administration of anti-ret-
roviral therapy and anti-malarial drugs [13]. Interactions
between quinine and nevirapine or ritonavir, including
ritonavir-boosted protease inhibitor regimens have been
reported. The concurrent administration of nevirapine
and quinine can lead to significant reductions in the
Table 1 Molecular marker codons
Dhfr genotype Pfcyt b genotype
aa
position
16 51 59 108 165 133 268 272 275 280 283 284
Wild type A N C S G M V K P G L V
Mutant
type
V I R N/T K I S/C R T D I K
Case
report(2)
A I R N K M V K P G I V
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efficacy of the quinine and increased toxicity [14]. The
co-administration of ritonavir and quinine can lead
to elevations in plasma levels of quinine and suggest
that quinine dosages should be shifted downward [15].
Anti-retroviral drugs are the most therapeutically risky
drugs for drug-drug interactions because of their potent
inhibition and induction of cytochrome enzymes. This is
particularly important during co-administration of lume-
fantrine (in combination with artemisinin derivates) and
protease inhibitors or non-nucleoside reverse transcrip-
tase inhibitor-based anti-retroviral regimens [16]. The
first patient received intravenous quinine and doxycycline
with a successful therapeutic response. Quinine therapy
was used because in Europe the available formulations of
intravenous artesunate recommended as the first-line by
WHO were not produced according to Good Manufac-
turing Practices (GMP). WHO recently pre-qualified
intravenous artesunate manufactured by Guilin Pharma-
ceuticals in China and this may resolve problems in
acquiring GMP artesunate in Spain [17].
In the second case, the patient was initially treated with
atovaquone/proguanil. Atovaquone-proguanil has shown
high efficacy against multi- drug-resistant P. falciparum
with few side effects and a mode of action unrelated to
that of other anti-malarial drugs [18], such as quinine,
plus one of the three following: doxycycline, tetracycline
or clindamycin and mefloquine. The patient developed an
early treatment failure (within 72 hours) with an elevation
of parasitaemia and a jump from 0.5% to 8% infected ery-
throcytes in the thick blood film. The malarial treatment
failures can be attributed to recrudescence of P. falci-
parum due to suboptimal therapy or anti-malarial drug-
resistant genotypes. Atovaquone is a low genetic barrier
drug but proguanil synergizes with atovaquone in combi-
nation, reducing the selection of resistance mutations.
Resistance to atovaquone and proguanil has been asso-
ciated with sequence changes in cytochrome b (cytb) and
dihydrofolate reductase (dhfr) gene respectively. Isolates of
P. falciparum collected by the European Network on
Imported Infectious Disease surveillance were analysed for
single-point mutations of the cytb gene and the results
showed a level < 1% of these mutations [19]. Atovaquone
inhibits electron transfer of the respiratory chain by bind-
ing to cytochrome b of plasmodial mitochondria. On the
other side, proguanil, as its active form cycloguanil, is an
inhibitor of the DHFR involved in pyrimidine biosysnth-
esis. However, in combination with atovaquone, by an
unknown mechanism, it lowers the effective concentration
at which the former collapses the mitochondrial mem-
brane potential [20]. In the second case, the analysis of
mutations of the DHFR and cytochrome b genes showed
the characteristic triple DHFR mutations associated with
failure for the treatment of pyrimethamine, but not of pro-
guanil. The cytb gene showed the mutation L283I. This
mutation, associated with V284K, shows a 76-fold increase
in IC50 of atovaquone compared to non-mutant strains,
but this effect must be the direct responsibility of V284K,
as I283 has been observed in atovaquone sensitive para-
sites [21]. The presence of the L283I mutation by itself
does not confer resistance to atovaquone. These data sug-
gest that the early treatment failure in the second patient,
could be more related to a suboptimal therapy than to a
drug-resistant genotype. Atovaquone/proguanil is used in
the treatment of uncomplicated multi- drug-resistant
P. falciparum malaria, but we do not have an answer to
this question: could the HIV-infected patients have also a
higher rate of atovaquone/proguanil treatment failure? No
data about this point have been reported in HIV-infected
patients. This question must be approached with caution.
An explanation could be a delayed parasite clearance due
to a slowness of action by atovaquone/proguanil, but the
parasitaemia increased from 0.5% to 8% on day 3. On the
other hand, treatment failure could be attributed to poor
bioavailability of the atovaquone, proguanil or its active
metabolite, cycloguanil. The biotransformation of progua-
nil could have been reduced. A possible interaction
between atovaquone/proguanil and IP-based regimens
could be presented [22]. However, it was not possible to
measure drug concentrations at that time.
In routine clinical practice, the PCR is performed on
admission samples to confirm the results obtained by
microscopy, as shown in this cases, and to avoid the lim-
itations of the microscopy and RDT: misdiagnosis of
mixed-species infections and low parasitaemia. The micro-
scopic examination of Giemsa-stained thin and thick
blood films remains the “gold standard” for the diagnosis
of malaria and detects parasites at a density of 50 para-
sites/μl by an experienced microscopist [23]. The RDT,
using a protein rich in histidine (HRP-2) and aldolase or
lactate dehydrogenase antigens, detects parasites quickly
and cheaply, but it cannot provide data regarding drug
resistance genotypes. RDT is accepted as an excellent tool
in the diagnosis of P. falciparum malaria. However, it is
not useful in the follow-up anti-malarial therapy, because
it could positive HRP-2 antigen for three or four weeks
after a successful therapy. The PCR-based methods are
extremely sensitive with a detection limit of < 10 para-
sites/μl. Various authors have reported the development of
a real-time PCR assay to detect P. falciparum, Plasmo-
dium vivax and Plasmodium ovale in routine clinical diag-
nosis [24]. The risks of contamination are minimal and
the result can be obtained in only 2 h. In the cases pre-
sented, molecular methods were essential for rapid and
accurate diagnosis and follow-up.
In conclusion, this are two cases of HIV-infected
patients with imported P. falciparum malaria, high parasi-
taemia, both severe clinical episodes with > 350 CD4 cell
count/μl, absence of chemoprophylaxis and successful
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response. Factors such as drug interactions and the possi-
ble implication of anti-malarial therapy bioavailability are
all especially interesting in HIV-malaria co-infections.
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